Tango Therapeutics (NASDAQ:TNGX) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $11.0, a high estimate of $13.00, and a low estimate of $8.00. Observing a downward trend, the current average is 24.66% lower than the prior average price target of $14.60.

Investigating Analyst Ratings: An Elaborate Study

The standing of Tango Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

For valuable insights into Tango Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Tango Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Delving into Tango Therapeutics's Background

Financial Insights: Tango Therapeutics

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Positive Revenue Trend: Examining Tango Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.15% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Tango Therapeutics's net margin excels beyond industry benchmarks, reaching -251.29%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Tango Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -12.23%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.95%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: Tango Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.16.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.